The latest improvement attempt is a tool created by the Isotretinoin Products Manufacturers Group (IPMG), the manufacturers responsible for the FDA-mandated REMS program.
The most common indication among the respondents with dermatologist recommendations for products requiring a medical card was for acne (68%), followed by psoriasis and rosacea (28% each).
At a meeting with the FDA, AADA representatives described the severe impact on patient access to treatment that is resulting from the issues with the iPLEDGE rollout.